Importance There are 30 million adults (12%) in the United States who have chronic
obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Inhaled corticosteroids (ICSs) are a mainstay of COPD treatment for patients with a history of
exacerbations. Initial studies evaluating their use as monotherapy failed to show an effect on …

Chronic obstructive pulmonary disease patient care must include confirming a diagnosis
with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that …

Background Chronic obstructive pulmonary disease (COPD) is the third most common
cause of death around the world. The affected patients suffer not only from impaired lung …

Background Chronic obstructive pulmonary disease (COPD) is associated with multiple
comorbidities, which impact negatively on patients and are often underdiagnosed, thus …

Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Higher levels of exercise capacity and physical activity are desired outcomes in the
comprehensive management of the COPD patient. In addition, improvements in exercise …